T-type calcium channels inhibitors: a patent review

Importance of the field: T-type calcium channels are transmembrane proteins that regulate calcium entry in the cell in a voltage-dependent manner. Intracellular calcium levels are the key to many physiological processes, ranging from neuron firing to cardiac pacemaking. Inhibition of T-type calcium channels is heralded as a potential treatment to peripheral and CNS disorders, including hypertension, heart failure, sleep, epilepsy, drug addiction and neuropathic pain. Areas covered in this review: A comprehensive summary of patent literature disclosing T-type calcium channels inhibitors is provided. What the reader will gain: In all, 46 patent applications including 15 chemical structure classes are reviewed. Available in vitro, in vivo and clinical results are also discussed. Take home message: Several selective T-type calcium channels inhibitors with demonstrated in vitro and in vivo effects, including one Phase I clinical candidate, are now available. While future clinical results will be paramount to assess target validity in patients, these novel inhibitors represent excellent tools to further investigate the role of T-type channels in pathophysiological conditions.

[1]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[2]  H. Rhim,et al.  Synthesis and evaluation of alpha,alpha'-disubstituted phenylacetate derivatives for T-type calcium channel blockers. , 2008, Bioorganic & medicinal chemistry letters.

[3]  Kyoichi Ono,et al.  Cardiac T-type Ca(2+) channels in the heart. , 2010, Journal of molecular and cellular cardiology.

[4]  Steven V. Fox,et al.  Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents. , 2010, ACS medicinal chemistry letters.

[5]  M. Doddareddy,et al.  Design, synthesis, and biological evaluation of 1,3-dioxoisoindoline-5-carboxamide derivatives as T-type calcium channel blockers. , 2007, Bioorganic & Medicinal Chemistry Letters.

[6]  R. Tsien,et al.  Nomenclature of Voltage-Gated Calcium Channels , 2000, Neuron.

[7]  Minsoo Han,et al.  Exploration of novel 2-alkylimino-1,3-thiazolines: T-type calcium channel inhibitory activity. , 2010, Journal of combinatorial chemistry.

[8]  Steven V. Fox,et al.  In Vitro Characterization of T-Type Calcium Channel Antagonist TTA-A2 and In Vivo Effects on Arousal in Mice , 2010, Journal of Pharmacology and Experimental Therapeutics.

[9]  V. Jevtovic-Todorovic,et al.  The role of T-type calcium channels in peripheral and central pain processing. , 2006, CNS & neurological disorders drug targets.

[10]  S. Nattel,et al.  Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. , 2001, Cardiovascular research.

[11]  D. Abernethy,et al.  Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist. , 1997, The American journal of cardiology.

[12]  E. E. van der Wall,et al.  T-channel-selective calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so far: a review of published data. T-Channel Calcium Channel Blocker Study Group. , 1999, American Journal of Therapeutics.

[13]  Ji-Hyung Seo,et al.  Antitumor activity of 3,4-dihydroquinazoline dihydrochloride in A549 xenograft nude mice. , 2010, Bioorganic & medicinal chemistry letters.

[14]  Ming Li,et al.  Calcium signaling and T-type calcium channels in cancer cell cycling. , 2008, World journal of gastroenterology.

[15]  H. Rhim,et al.  Synthesis and SAR studies of a novel series of T-type calcium channel blockers. , 2006, Bioorganic & medicinal chemistry.

[16]  T. Snutch,et al.  Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels , 2000, Neuropharmacology.

[17]  Jungahn Kim,et al.  3D QSAR studies on 3,4-dihydroquinazolines as T-type calcium channel blocker by comparative molecular similarity indices analysis (CoMSIA). , 2010, Bioorganic & medicinal chemistry letters.

[18]  M. Barton,et al.  The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil. , 2005, European journal of pharmacology.

[19]  Daniel L Cheney,et al.  Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core. , 2008, Bioorganic & medicinal chemistry letters.

[20]  Steven V. Fox,et al.  Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists. , 2010, ACS medicinal chemistry letters.

[21]  Edmund M. Talley,et al.  Differential Distribution of Three Members of a Gene Family Encoding Low Voltage-Activated (T-Type) Calcium Channels , 1999, The Journal of Neuroscience.

[22]  J. Gomora,et al.  Mibefradil potently blocks ATP-activated K(+) channels in adrenal cells. , 1999, Molecular pharmacology.

[23]  P. Lory,et al.  T-Type Calcium Channels Are Inhibited by Fluoxetine and Its Metabolite Norfluoxetine , 2006, Molecular Pharmacology.

[24]  W. Greenlee,et al.  T-type calcium channel blockers: spiro-piperidine azetidines and azetidinones-optimization, design and synthesis. , 2010, Bioorganic & medicinal chemistry letters.

[25]  M. Brini,et al.  Calcium signalling: a historical account, recent developments and future perspectives , 2000, Cellular and Molecular Life Sciences CMLS.

[26]  Hee-Sup Shin,et al.  T-type calcium channels and thalamocortical rhythms in sleep: a perspective from studies of T-type calcium channel knockout mice. , 2007, CNS & neurological disorders drug targets.

[27]  M. G. Rimoli,et al.  T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin , 2009, Neuropharmacology.

[28]  Steven V. Fox,et al.  Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. , 2008, Journal of medicinal chemistry.

[29]  M. Doddareddy,et al.  Synthesis and biological evaluation of novel T-type Ca2+ channel blockers. , 2004, Bioorganic & medicinal chemistry.

[30]  H. Satoh.  Role of T-type Ca2+ channel inhibitors in the pacemaker depolarization in rabbit sino-atrial nodal cells. , 1995, General pharmacology.

[31]  Steven V. Fox,et al.  Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists. , 2010, Bioorganic & medicinal chemistry letters.

[32]  Olivier Poirot,et al.  Silencing of the Cav3.2 T‐type calcium channel gene in sensory neurons demonstrates its major role in nociception , 2005, The EMBO journal.

[33]  Daesoo Kim,et al.  Lack of the Burst Firing of Thalamocortical Relay Neurons and Resistance to Absence Seizures in Mice Lacking α1G T-Type Ca2+ Channels , 2001, Neuron.

[34]  N. Akaike,et al.  Actions of Ca2+ antagonists on two types of Ca2+ channels in rat aorta smooth muscle cells in primary culture. , 1990, Circulation research.

[35]  S. Doran,et al.  Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice. , 2009, The Journal of clinical investigation.

[36]  H. Rhim,et al.  Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity. , 2010, Bioorganic & medicinal chemistry.

[37]  J. Uslaner,et al.  T-Type Calcium Channel Antagonism Decreases Motivation for Nicotine and Blocks Nicotine- and Cue-Induced Reinstatement for a Response Previously Reinforced with Nicotine , 2010, Biological Psychiatry.

[38]  K. Dyason,et al.  Scorpion toxins that block T-type Ca2+ channels in spermatogenic cells inhibit the sperm acrosome reaction. , 2003, Biochemical and biophysical research communications.

[39]  Gerald W. Zamponi,et al.  Role of voltage-gated calcium channels in ascending pain pathways , 2009, Brain Research Reviews.

[40]  Steven V. Fox,et al.  Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist. , 2008, Journal of medicinal chemistry.

[41]  T. Smith,et al.  T-type Ca2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. , 1994, Circulation research.

[42]  Bong Young Chung,et al.  Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers. , 2006, Bioorganic & medicinal chemistry letters.

[43]  Luping Z. Huang,et al.  Selective blockade of T-type Ca2+ channels suppresses human breast cancer cell proliferation. , 2008, Cancer letters.

[44]  S. D. Kimball,et al.  High affinity interaction of mibefradil with voltage‐gated calcium and sodium channels , 2000, British journal of pharmacology.

[45]  K. Campbell,et al.  Attenuated pain responses in mice lacking CaV3.2 T‐type channels , 2007, Genes, brain, and behavior.

[46]  H. Rhim,et al.  3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. , 2004, Bioorganic & medicinal chemistry letters.

[47]  H. Rhim,et al.  Growth inhibition of human cancer cells in vitro by T-type calcium channel blockers. , 2006, Bioorganic & medicinal chemistry letters.

[48]  H. Zhuang,et al.  NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-Benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: A New Selective Inhibitor of T-Type Calcium Channels , 2004, Journal of Pharmacology and Experimental Therapeutics.

[49]  F. Hofmann,et al.  Antihypertensive Effects of the Putative T-Type Calcium Channel Antagonist Mibefradil Are Mediated by the L-Type Calcium Channel Cav1.2 , 2005, Circulation research.

[50]  H. Zhuang,et al.  A role of functional T-type Ca2+ channel in hepatocellular carcinoma cell proliferation. , 2009, Oncology reports.

[51]  B. Nilius,et al.  Inhibition by mibefradil, a novel calcium channel antagonist, of Ca2+‐ and volume‐activated Cl− channels in macrovascular endothelial cells , 1997, British journal of pharmacology.

[52]  M. de Curtis,et al.  Selective increase in T-type calcium conductance of reticular thalamic neurons in a rat model of absence epilepsy , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[53]  H. Rhim,et al.  T-type Ca2+ channel blockers suppress the growth of human cancer cells. , 2008, Bioorganic & medicinal chemistry letters.

[54]  Gail Mandel,et al.  Nomenclature of Voltage-Gated Sodium Channels , 2000, Neuron.

[55]  H. Rhim,et al.  Synthesis and biological activity of 3,4-dihydroquinazolines for selective T-type Ca2+ channel blockers. , 2005, Bioorganic & medicinal chemistry letters.

[56]  Steven V. Fox,et al.  Positive Allosteric Interaction of Structurally Diverse T-Type Calcium Channel Antagonists , 2009, Cell Biochemistry and Biophysics.

[57]  P. Dayer,et al.  Drug–drug interactions of new active substances: mibefradil example , 1999, European Journal of Clinical Pharmacology.